Mobi724 Global Solutions Inc. (MOS:CSE) Announces Bought Deal
Mobi724 Global Solutions Inc. Announces Bought Deal Financing
Momentum Public Relations
Press Release: April 04, 2017
Mobi724 Global Solutions Inc. (“Mobi724” or the “Company“) (CSE:MOS)(CSE:MOS.CN) – a Fintech leader offering all in one fully integrated EMV payment, card link couponing and digital marketing solutions, announces that it has entered into an agreement with GMP Securities L.P. (the “Underwriter“) for a “bought deal” private placement offering of special warrants of the Company (the “Special Warrants“) at a price per Special Warrant of $0.35 for aggregate gross proceeds of approximately $5 million (the “Offering“).
Each Special Warrant will entitle the holder thereof to receive and without payment of additional consideration, one (1) unit of the Company (each a “Unit” and collectively the “Units“) consisting of one (1) Common Share (each a “Unit Share“) and one-half of one (0.5) common share purchase warrant (each whole common share purchase warrant a “Warrant“). Each whole Warrant, subject to customary adjustments, shall be exercisable into one (1) Common Share (a “Warrant Share“) at an exercise price of $0.46 per Warrant Share for a period of two (2) years from the date of issue. If the volume weighted average price of the Common Shares on the CSE is equal to or greater than $0.65 for a period of 10 consecutive trading days then the Company may anytime thereafter accelerate the expiry date of the Warrants to the date that is 30 days following the date on which the Company issues notice to all the Warrant holders of the new expiry date. The Company will also issue a press release on the same date as it issues notice confirming the new expiry date of the Warrants.
The Company has agreed to use its reasonable commercial best efforts to obtain a receipt for a final short form prospectus qualifying the distribution of the Units upon exercise of the Special Warrants (the “Qualification Condition“) on or before the date that is 90 days following closing of the Offering (the “Qualification Deadline“). If the Prospectus Qualification does not occur before the Qualification Condition, each holder shall be entitled to receive, without payment of additional consideration, 1.05 Units per Special Warrant. Unless the Qualification Condition occurs, securities issued in connection with the Offering will be subject to a four-month hold period from the date of issue.
The closing of the Offering is subject to the completion of formal documentation, including but not limited to, the execution of an underwriting agreement with the Underwriter in connection with the Offering and receipt of any required regulatory approvals, including approval of the CSE. All securities issued pursuant to the Offering will be subject to a statutory hold period expiring four months and one day after closing of the Offering. Closing of the Offering is expected to occur on or about April 18, 2017 or such other date as the Underwriter and the Company may agree.
The Company intends to apply to have its Common Shares listed on the TSX Venture Exchange. There can be no assurance that such a listing would occur.
Mobi724 intends to use the net proceeds of the Offering for general corporate purposes.
This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act“) or any state securities laws and may not be offered or sold within the United States unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.
For more information, please visit www.mobi724globalsolutions.com.
About Mobi724 Global Solutions
Mobi724, a leader in the fintech industry based in Montreal (Canada), offers a unique and fully integrated suite of payment & digital marketing solutions with a combined EMV Payment, Card Linked Offers, and Digital Marketing platform that works on any card and any mobile device. Mobi724’s solutions add value to all types of transactions benefiting banks, retailers and cardholders by leveraging available user and purchasing data to increase transaction volumes and spend. Mobi724 provides a turnkey solution to its clients to capture card transactions on any mobile device, at any point of sale or from any payment card. Mobi724 provides its customers with full and comprehensive traceability and enriched consumer data through its offering. Its solutions enables card associations, retailers, manufacturers, offer providers, mobile operators and card issuers to create, manage, deliver and “track and measure” incentive campaigns worldwide to any mobile device and allow its redemption at any point of sales.
- Published in Financial Technology, Mobi724 Global Solutions, Mobile Technology, News Home, Technology
HealthSpace (HS:CSE) CEO Provides Update
HealthSpace Data Systems Ltd. (the “Company” or “HealthSpace”) is pleased to provide an update of the Company.
Peter C. Smyrniotis, CEO of Healthspace comments, “I am pleased to provide an update on the progress of our Company. Since I took on the role of CEO this past November 2016, we have achieved a great deal within our organization and I see a tremendous opportunity for growth moving forward.”
HealthSpace’s list of accomplishments and strategic initiatives include the following:
1.Financial Overview:
The management team worked diligently in 2016 to reorganize, restructure and recapitalize the company. The result is a streamlined internal cost structure and a stronger balance sheet, which has put the Company on much stronger financial footing. On a normalized basis the Company is currently operationally EBITDA positive and fully expects to remain as such moving forward.
2.HS Cloud Suite Pro Launch:
The Company delivered to market for both government and commercial enterprise clients the first release of its new flagship Software-as-a-Service (SaaS) platform developed to work across browsers; available in native apps in iOS, Android, and Windows; and connected to a reporting and API integration tool, this technology stack is powerful and elastic in its market applications for environmental health auditing and reporting.
3.HS Data:
Working with its technology partner Keboola, the Company has prioritized designing and developing an enhanced HS Data application for existing government customers to address a market opportunity and in turn generate a dedicated revenue channel from this new application’s deployment.
4.Commercial Enterprise Market Launch:
With the completion of HS Cloud Suite Pro, Healthspace is now engaging with food & beverage, hospitality, assisted living, child-care, water monitoring and other prospective customers.
5.Expansion of the Advisory Board:
The Company has been able to connect and onboard new members to its advisory board, with more than 100 years of experience in food & beverage, hospitality, and franchises; experience scaling enterprise SaaS ventures both in Canada and internationally.
6.Food & Beverage Market:
This is the Company’s first commercial enterprise vertical engagement. Healthspace’s government customers inspect more of these types of sites than any other on a monthly basis. Further, Healthspace’s discoveries with prospective clients in this space has demonstrated to the Company that there is a trifecta of requirements from this vertical, as they have budget available to use technology to improve their businesses’ performance, multiple champions internally within organizations that service locations across multiple jurisdictions, and finally a use-case to gain visibility and predictability into their organization’s environmental health services positioning.
7.Cannabis Environmental Health Service:
This is a market opportunity that the Company is actively exploring. Healthspace has identified and are currently in discussions with several potential channel partners to provide its expertise in environmental health and safety inspection technology. As regulatory compliance becomes an increasing issue in this new high growth market Healthspace sees a tremendous opportunity for the application of our technology and expertise.
Peter C. Smyrniotis further comments, “In addition to all the above accomplishments having transpired or commenced, I am also pleased to update that HealthSpace continues to win new government opportunities across the US and Canada in which we currently service over 300 jurisdictions. Almost all of these new customers are onboarding our new HS Cloud Suite Pro platform, which delivers cloud-enabled, iterative, and multi-endpoint supported solutions. From these new customers to smaller renewals, all of our customers will benefit from our SaaS offerings going forward.
2017 is the year that we move our new software sales to the enterprise SaaS modality, which benefits our customers with responsive, iterative software; our employees with the ability to work on a contemporary technology platform which they can drive real value into; and to our shareholders who gain all the economic upside of a SaaS enterprise venture.
In summary, I believe that we now have the best possible combination of technology tools within our new platform to further increase our market penetration within the government sector. The coming quarters of 2017 should be an exciting time for our company as our management and advisory team focus their energies on the launch of our platform to commercial enterprise organizations such as food & beverage as well as the cannabis and water monitoring space. These commercial business segments dramatically increases our total available market opportunity and adds multiple new lines of revenue with faster sales cycles.
Taking all the above into account, I believe that the year ahead will be an exciting one for HealthSpace and an opportunity to build exceptional value for shareholders. I look forward to providing further updates and thank you for your continuing support of our efforts.”
HealthSpace Data Systems Ltd.
HealthSpace is an industry leading technology company currently providing inspection, information, communication and data management systems for federal, state, county and municipal governments. Over the last decade, HealthSpace has successfully developed both enterprise and mobile internet-based applications currently serving over 300 state and local government organizations across North America. HealthSpace currently offers the only integrated inspection, administration and analytics product suite across all platforms in North America. Further, HealthSpace now delivers its government grade technologies to private businesses enabling them to gain visibility and predictability into their own organizations and move from a reactive to a proactive operational status. HealthSpace continues to deliver focused service and innovative solutions to government organizations, while expanding into commercial enterprise verticals to enable new customers with proactive environmental health best practices and policies.
For more information please contact:
Peter Smyrniotis, CEO
peter@hscloudsuite.com
1-604-763-2552
Peter J. Kletas
PJK & Associates Inc.
1-866-999-6251
- Published in Health Space, Life Sciences, Medical Marijuana, News Home
Tetra Bio-Pharma and IntelGenx Announce the Signing of a Definitive Agreement for the Development and Commercialization of a Dronabinol XL Tablet
IntelGenx and Tetra Bio-Pharma Announce the Signing of a Definitive Agreement for the Development and Commercialization of a Dronabinol XL Tablet
Tetra Bio-Pharma Inc. (“Tetra“) (CSE:TBP)(OTC PINK:GRPOF) and IntelGenx Corp. (“IntelGenx”) (TSX VENTURE:IGX)(OTCQX:IGXT), today announced the signing of a definitive agreement for the development and commercialization of a drug product containing the cannabinoid Dronabinol (the “Product”) for the management of anorexia and cancer chemotherapy-related pain. This definitive agreement follows the binding term sheet between the two companies that was announced on February 9, 2017.
Pursuant to the definitive agreement, Tetra has exclusive rights to sell the Product in North America, with a right of first negotiation for territories outside of the United States and Canada. Tetra will make an upfront payment to IntelGenx, in addition to set future milestone and royalty payments, based on the completion of an efficacy study, approvals from the U.S. Food and Drug Association (“FDA”) and Health Canada, and the commercial launch of the Product. IntelGenx will be responsible for the research and development of the Product, including clinical studies, and will develop the product as an oral mucoadhesive tablet based on its proprietary AdVersa® controlled-release technology. Tetra will be responsible for funding the product development, and will own and control all regulatory approvals, including the related applications, and any other marketing authorizations. Tetra will also be responsible for all aspects of commercializing the Product.
“The U.S. cancer pain market is expected to reach $5 billion in 2018, and the quick growing medical cannabis industry is poised to capture a signature portion of that opportunity,” said Dr. Horst G. Zerbe, President and CEO of IntelGenx. “We are pleased to be working with Tetra to bring this much-needed cannabinoid product to North American patients suffering from anorexia and cancer chemotherapy-related pain.”
“We are pleased to announce the signing of the definitive agreement with IntelGenx and look forward to working very hard with them to bring this much-needed product to patients suffering from cancer pain,” said Andre Rancourt, CEO of Tetra. “The execution of this agreement is just the beginning for Tetra as we look forward to aggressively concluding future agreements as we build a leading bio-pharmaceutical organization focused on developing medicinal cannabis as pharmaceutical drugs.”
Background Information
There are many clinical problems associated with the use of currently available form of Dronabinol in patients with anorexia and cancer chemotherapy-related pain. It has been demonstrated that psychoactive drugs exert their euphoria, and other psychoactive effects, when the blood levels of the drug rapidly increase. The pharmacokinetic profile of tetrahydrocannabinol (“THC”) and its metabolite increases the abuse potential of cannabinoids like Dronabinol. The significant advantage of an oral mucoadhesive tablet based on IntelGenx’ proprietary AdVersa®controlled-release technology is that it can be adjusted to achieve a predetermined drug release pattern by increasing the residence time, promoting intimate contact with the mucosal tissue and increasing the bioadhesive properties of the dosage form. It is believed that, by deploying this technology in the controlled-release of THC, a longer time release of the drug will be achieved and, thereby, a rapid increase in the blood will be avoided. There will also potentially be improved bioavailability and reduced gastro-intestinal side effects, making a sustained-release THC product a promising alternative in the battle for the reduction of opioids in patients with chronic pain.
About Tetra Bio Pharma
Tetra Bio Pharma is a multi-subsidiary publicly traded company (CSE:TBP) (OTC PINK:GRPOF) engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.
Tetra Bio Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. More information is available about the company at: www.tetrabiopharma.com.
About IntelGenx
IntelGenx is a leading oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm™ technology platform. Established in 2003, the Montreal-based company is listed on the TSX-V and OTC-QX.
IntelGenx highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx state-of-the art manufacturing facility, established for the VersaFilm™ technology platform, supports lab-scale to pilot and commercial-scale production, offering full service capabilities to our clients. More information is available about the company at: www.intelgenx.com.
- Published in Life Sciences, Medical Marijuana, News Home, Tetra Bio Pharma
AtmanCo’s Psychometric Test Will Soon be Offered to University Students in the United States
AtmanCo’s Psychometric Test Will Soon be Offered to University Students in the United States
– Momentum Public Relations –
Press Release: March 31, 2017
The Atman psychometric test will be offered to university students in the American market through a promotional campaign co-launched with Sparkroom
AtmanCo Inc. (TSX VENTURE:ATW) announced today that it has partnered with Sparkroom, a leader in student recruitment, providing fully transparent, data-driven strategies designed to achieve enrollment objectives.
Sparkroom’s Student Acquisition Platform is a preferred tool for North American universities to recruit new students. This partnership between AtmanCo and Sparkroom will introduce an advertising campaign for AtmanCo’s B2C version of its renowned psychometric test through MTVU in May of this year. MTVU is directly linked to university campuses in the United States, with exposure to more than 3 million students and reaches an audience of 11 million people through their MTVU channel.
AtmanCo’s B2C product, bloomed.com, will serve as a web platform for this advertising campaign by offering students a psychometric test to discover their personality profile. The personalized results will help students:
- Succeed academically,
- integrate into the student life on campus, and
- Find the most compatible people to build the best in-class groups.
“We are pleased to announce the partnership with Sparkroom on this marketing campaign, which is in line with AtmanCo’s customer acquisition and big data implementation goals. Furthermore, we are delighted to be able to reach new markets with our API and its many applications. Sparkroom points out that students need all the tools to help with personal development, and personality testing is an ideal way to understand one’s self. The success of this project is based on the enthusiasm of young people to learn about themselves”, said Michel Guay, founder, president, chief executive officer and chairman of the Board of AtmanCo.
ABOUT SPARKROOM
Through the deployment of award-winning technology and services, Sparkroom helps higher education marketers rapidly grow their enrollment volume. Sparkroom marketing technology and services address the full student lifecycle, with a focus on delivering higher-quality prospects and better conversion rates. Our full-service solutions are designed to measure marketing effectiveness in relation to student recruitment efforts.
– Sparkroom performance marketing technology integrates campaign data, automates processes based on performance and provides holistic cross-channel attribution reporting and analytics, including cross-channel dashboards.
– Sparkroom enrollment marketing services include demand generation and student recruitment support to manage cross-channel marketing campaigns from strategy to execution to optimization and beyond.
– Sparkroom enrollment management solutions, inclusive of enrollment management consulting and short OPM engagements, layer on operational services for institutions in need of end-to-end support.
ABOUT ATMANCO
AtmanCo is the publisher of a scientifically validated psychometric test. Through the HR cloud platform or the application program interface (API), the results allow the companies to optimize the talents of their human capital by improving the recruiting and organizational development success rate. AtmanCo’s solutions also enable impacting the major consumer market by easily integrating them with our partners’ technological solutions. For more information, follow us at @atmanco and on LinkedIn. AtmanCo is also the owner of RNIS Telecommunications inc (‘VoxTel’) which owns the online dating site Quebec Rencontres as well as offering various interactive and billing wireless and landline telephone solutions.
The TSX Venture Exchange and its Regulatory Services provider (as per meaning assigned to this term in TSX Venture Exchange’s policies) bear no liability as to the relevance or accuracy of this press release.
Forward looking statements
This press release contains forward-looking statements that reflect the Company’s current expectation regarding future events. There is a risk that expectations and forward-looking statements will not prove to be accurate. Readers are cautioned not to place undue reliance on these forward-looking statements as they involve risks and uncertainties, which could make actual results differ materially from those projected herein and depend on a number of factors including, but not limited to, no history of profitability, future financing, intellectual property and patents, key personnel, competitive marketplace, technology obsolescence, share price volatility and other risks detailed from time to time in the Company’s filings. While AtmanCo anticipates that subsequent events and developments may cause its views to change, AtmanCo specifically disclaims any obligation to update these forward looking statements, unless obligated to do so by applicable securities laws
Additional information regarding the Company are available on SEDAR www.sedar.com
AtmanCo Inc.
Michel Guay
Founder, president and CEO
1.877.935.5959 ext. 301
mguay@atmanco.com
Stephane Poirier
VP Marketing & Technologies
1.877.935.5959 ext. 310
spoirier@atmanco.com
atmanco.com
© 2017 Canjex Publishing Ltd. All rights reserved.